Human parvovirus B19: Prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients

Vox Sanguinis

Volumn 75, Issue 2, 1998, Pages 97-102

  Jordan, Jeanne A ^a   Tiangco, B ^b   Kiss, J ^c   Koch, W ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; HUMAN; NORMAL HUMAN; PARVOVIRUS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; SCREENING;

ANEMIA; ANTIBODIES; BLOOD DONORS; BLOOD TRANSFUSION; DNA, VIRAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; UNITED STATES; VIRAL ENVELOPE PROTEINS;

EID: 0031721016     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030968     Document Type: Article

References (23)

1. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DAJ: Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-265.
2. Prowse C, Ludlam CA, Yap PL: Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
3. Zanella A, Rossi F, Cesana C, Foresti A, Nador F, Binda AS, Lunghi G, Cappellini MD, Furione M, Sirchia G: Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 1995;35:769-772.
4. Morfini M, Longo G, Ferrini PR, Azzi A, Zakrewska C, Ciappi S, Kolumban P: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus. Am J Hematol 1992;39:149-150.
5. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1975;1:72-73.
6. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P: Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993;31:323-328.
7. Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JAJ: Blood donor screening for parvovirus B19. J Virol Methods 1990;30:233-238.
8. Tsujimura M, Matsushita K, Shiraki H, Sato H, Okochi K, Maede Y: Human parvovirus B19 infection in blood donors. Vox. Sang 1995;69: 206-212.
9. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Oda T, Katoh T, Takahashi T, Sekiguchi S, Chiba S: Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995;91: 1017-1018.
10. Mosley JW: Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates? Transfusion 1994; 34:744-746.
11. Luban NLC: Human parvoviruses: Implications for transfusion medicine. Transfusion 1994;34: 821-827.
12. Barbara JAJ, Contreras M: Infectious complications of blood transfusion; in Contereras M (ed): ABC of transfusion. London, BMJ Publishing Group, 1990, pp 49-52.
13. Jordan JA: Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996;174: 37-42.
14. Cohen BJ, Hall SM: Parvovirus B19; in Greenough A (ed): Congenital, Perinatal and Neonatal Infections. New York, Churchill Livingstone 1992, pp 157-170.
15. Koch WC: A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays. J Virol Methods 1995;55:67-82.
16. Jordan JA, Faas SJ, Braun ER, Trucco M: Exonuclease-released fluorescence detection of human parvovirus B19 DNA. Mol Diagn 1996;1: 321-328.
17. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS: Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321: 519-523.
18. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988;ii:1159-1162.
19. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS: Chronic bone marrow failur due to persistent B19 parvovirus infection. N Engl J Med 1987;317:287-294.
20. Gahr M, Pekrum A, Eiffert H: Persistence of parvovirus B19-DNA in blood of a child with severe combined immunodeficiency associated with chronic pure red cell aplasia. Eur J Pediatr 1991;150:470-472.
21. Langnas AN, Markin RS, Cattral MS, Naides SJ: Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 1995;22:1661-1665.
22. Metzman R, Anand A, DeGiulio PA, Knisely AS: Hepatic disease associated with intrauterine parvovirus B19 infection in a newborn premature infant. J Pediatr Gastroenterol Nutr 1989;9:112-114.
23. White FV, Jordan JA, Dickman PS, Knisely AS: Fetal parvovirus B19 infection and liver disease of antenatal onset in an infant with Ebstein's anomaly. Pediatr Pathol 1995;15:121-129.